Director and Chief Physician of the Department of Integrated Traditional Chinese and Western Medicine and Geriatric Oncology. With over 30 years of clinical experience in oncology integrating traditional Chinese and Western medicine, specializing in the combined treatment of common malignant tumors such as lung cancer, digestive system tumors, and breast cancer. Accumulated extensive clinical expertise in postoperative consolidation therapy to prevent recurrence and metastasis, as well as in enhancing therapeutic efficacy, alleviating adverse reactions, and improving quality of life through the application of traditional Chinese medicine during radiotherapy and chemotherapy. Current positions include Vice Chairman of the Tumor Professional Committee of the China Association for Research and Promotion of Traditional Chinese Medicine, Vice Chairman of the Integrated Traditional Chinese and Western Medicine Cervical Cancer Professional Committee of the China Anti-Cancer Association, Chairman of the Integrated Traditional Chinese and Western Medicine Professional Committee of the Beijing Anti-Cancer Association, Chairman-designate of the Traditional Chinese Medicine Branch of the Beijing Cancer Prevention and Treatment Research Association, and Vice Chairman of the Tumor Professional Committee of the Beijing Association of Integrated Traditional Chinese and Western Medicine. Awarded the title of "Capital Young and Middle-aged Famous Traditional Chinese Medicine Practitioner" in 2021. Received the "Chinese Medicine Contribution Award" at the "Revere Life, Honor Healers" event in 2023. Has led multiple capital research projects and Beijing Traditional Chinese Medicine science and technology projects, and participated as a sub-center principal investigator in several clinical studies under the National Eleventh Five-Year Plan, Twelfth Five-Year Plan, and Ministry of Science and Technology projects. As the second completer, participated in the study "Effects and Mechanisms of Traditional Chinese Medicine Intervention on Adverse Reactions of Endocrine Therapy for Breast Cancer," which won the Second Prize of the Ministry of Education's Science and Technology Progress Award. As the Principal Investigator, led the "Multicenter Randomized Double-Blind Placebo-Controlled Clinical Study of Renshen Yangrong Decoction in Alleviating Fatigue in Chemotherapy Patients," the results of which were selected for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.